New Study Says I Was Wrong About NMN and NR?

Key Takeaways

• Small Bergen study favors NR, but larger trial shows parity
• Both NR and NMN convert to nicotinic acid via microbes
• NAD rise does not translate into measurable functional improvements
• Meta‑analyses find no significant metabolic or strength benefits
• Exercise remains most effective, low‑cost NAD support strategy

Pulse Analysis

The rivalry between nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has driven a multi‑billion‑dollar supplement market, yet recent human data suggest the debate may be a red herring. A six‑subject crossover trial from Norway reported a 2.3‑fold greater NAD increase with NR, but its limited sample size and high variability undermine confidence. In contrast, a robust 65‑participant, double‑blind study published in Nature Metabolism showed comparable NAD doubling for both compounds, effectively nullifying claims of a clear winner. These divergent outcomes underscore the importance of study scale and reproducibility when evaluating nutraceutical efficacy.

Beyond raw NAD numbers, mechanistic insights are reshaping the conversation. Multiple investigations—including isotope‑label tracing in Princeton labs and ex‑vivo fecal incubations—demonstrate that orally administered NR and NMN are rapidly de‑ribosylated by gut microbiota, yielding nicotinic acid, the cheaper vitamin B3 form. This nicotinic acid then feeds the Preiss‑Handler pathway, converging both supplements onto a shared metabolic route. The implication is that the premium price of NR or NMN may largely reflect a delivery vehicle rather than a distinct biochemical advantage, prompting regulators and investors to scrutinize the true value proposition.

Clinically, the story remains sobering. Meta‑analyses of randomized trials in older adults reveal no significant gains in muscle mass, strength, gait speed, or metabolic markers despite confirmed NAD elevation. A long‑COVID cohort receiving NR also failed to show symptom improvement over placebo. While niche sub‑populations might still benefit, the bulk of evidence suggests that lifestyle interventions—particularly regular aerobic exercise—remain the most cost‑effective strategy to sustain NAD pools and promote healthy aging. Stakeholders should therefore weigh the modest biochemical gains against the lack of demonstrable health outcomes when considering NR or NMN supplementation.